Ecto-5'nucleotidase (5'NT; CD73) expression was studied with a monoclonal antibody (7G2) and a radiochemical assay and compared with the expression of other antigens in B-cell-lineage leukemias on cells from 100 leukemic patients and two cell lines. A B-cell origin was confirmed by the expression of CD19 and HLA-DR. Four stages of B-cell leukemias were defined: stage I (pro-B) as CD10-, cytoplasmic p-(cp-), surface lg-(slg-); stage II (CALL) as CDlO+/cp-/ slg-; stage 111 (pre-B) as CDlO+"'-/cp+/slg-; and stage IV (B) as CDlO-/cp-/slg+. A linear correlation was found between immunohistochemical and radiochemical determination of 5'NT (r = -86). 5'NT expression was low in T-cell leukemias and stage 1, high in stages II and 111, and low again in stage IV of B-cell leukemias. 5'NT expression was not related t o cp, CTO-S'NUCLEOTIDASE (5"T) is an enzyme detect-E able on the external surface of the plasma membrane of B and T lymphocytes. Several authors have suggested that the enzyme is associated with B-cell maturation but the data on this subject are sometimes conflicting. Boss et all reported that B cells acquire surface Igs (sIgs) before the acquisition of 5'NT. It was later found that the increase in 5'NT activity of B lymphocytes precedes their acquisition of a capacity for IgG secretion.*.' Sengupta et a14 showed that two pre-B-cell lines (cytoplasmic p,'; cp,+) were 5'NT+, whereas 9 of 11 lymphoma cell lines (both IgG secreting and non-secreting) were 5'NT-. Four myeloma lines and 13 of 15 normal B-cell lines were 5'NTf. However, Nakae et a15 could not detect significant differences in 5'NT activity between precursor B-cell and Ig-secreting lymphoblastic cell lines. In all studies mentioned, the earliest stage studied was the pre-B cell. No studies have been published that compared the expression of 5'NT with that of other B-cell surface antigens in the earlier stages of B-cell development.
E able on the external surface of the plasma membrane of B and T lymphocytes. Several authors have suggested that the enzyme is associated with B-cell maturation but the data on this subject are sometimes conflicting. Boss et all reported that B cells acquire surface Igs (sIgs) before the acquisition of 5'NT. It was later found that the increase in 5'NT activity of B lymphocytes precedes their acquisition of a capacity for IgG secretion.*.' Sengupta et a14 showed that two pre-B-cell lines (cytoplasmic p,'; cp,+) were 5'NT+, whereas 9 of 11 lymphoma cell lines (both IgG secreting and non-secreting) were 5'NT-. Four myeloma lines and 13 of 15 normal B-cell lines were 5'NTf. However, Nakae et a15 could not detect significant differences in 5'NT activity between precursor B-cell and Ig-secreting lymphoblastic cell lines. In all studies mentioned, the earliest stage studied was the pre-B cell. No studies have been published that compared the expression of 5'NT with that of other B-cell surface antigens in the earlier stages of B-cell development.
From several studies of acute lymphoblastic leukemia (ALL) it is known that CD10' cells can have high 5'NT CD20, CD21, CD22, CD34, and terminal deoxynucleotidyl transferase (TdT) expression, but was significantly related t o CDlO and inversely related t o d h expression. However, the 5'NT activity in CD10+ leukemias (stages II and 111) shows a very wide range. Within the group of CD10' leukemias no differences were detected between 5'NT+ and 5'NT-cells in their expression of other B-cell antigens. We conclude that the place of 5'NT in leukemias corresponding t o early stages of B-cell development has been characterized. 5'NT is expressed in CDlO+ stages and decreases before the expression of slgs. Future studies should make clear whether a high expression of this enzyme in CD10' stages is a normal maturation phenomenon or a malignant phenomenon. The scarce data in these studies about 5'NT activity in the so-called non-T, non-B ALL and null-ALL stages have to be viewed with great care because these groups were poorly defined. The classification into these groups is out of date with the acquisition of new monoclonal antibodies (MoAbs) that define differentiation antigens. Also, MoAbs against 5'NT (CD73) have been developed recently." The aim of the present study was to define the expression of 5'NT in leukemias corresponding to the earliest stages of B-cell differentiation. Therefore, immunocytochemical and radiochemical detection of the enzyme was compared with the expression of other differentiation antigens.
MATERIALS AND METHODS
Reagents. The CD3, CD4, CD7, CD8, CD10, and CD34 MoAbs were purchased from Sanbio (Uden, The Netherlands); CD2, HLA-DR, K, and h from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands); CD19, CD22, and terminal deoxynucleotidyl transferase (TdT) from DAKO (ITK Diagnostics, de Kwakel, The Netherlands); CD20 from Becton Dickinson (Etten-Leur, The Netherlands); and CD21 from Coulter Clone (Hialeah, FL). The CD73 antibody used was 7G2.'* Fluorescein isothiocyanate (FITC)-conjugated antimouse IgG was from DAKO. [8-14C]-inosine monophosphate (IMP; 50 pCi/mL, specific activity 56 mCiimmo1) was derived from Amersham International (Buckinghamshire, UK); a$-methylene adenosine diphosphate (AOPCP), IMP, inosine, hypoxanthine, and adenosine from Sigma (St Louis, MO). Plastic sheets precoated with 0.1 mm polyethyleneimine (PE1)-cellulose were from Merck (Darmstadt, Germany).
Cells were obtained from bone marrow and peripheral blood samples of 100 leukemic patients, 97 patients with ALL, and three with chronic lymphocytic leukemia (CLL). The study was approved by the Institutional Review Board. Informed consent was obtained in each case according to the Declaration of Helsinki. In addition, two lymphoblastic cell lines, WI-L2 and 1254, were used." Mononuclear cells were isolated on a Ficoll Isopaque gradient and in most cases used after cryopreservation as described before.14 Immunohistochemistry. Immunoperoxidase staining was performed using cytospun cells to detect cb. Aliquots of 50 WL of 0.5 X lo6 cells/mL Earle's balanced salt solution with 5% human serum albumin were cytocentrifuged and dried on silica-gel. Cells were Celt's. 
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fixed in buffered formaldehyde acetone (4°C) for 30 seconds. After rinsing with water and phosphate-buffered saline (PBS), cells were incubated with 50 pL of MoAbs at room temperature for 60 minutes. Next, the slides were rinsed with PBS three times. Rabbit antimouse peroxidase with 2% pooled human serum was added for 60 minutes. Peroxidase staining was performed using diamino benzidine with 0.05 mol/L imidazole in 0.05 molL Tris buffer (pH 7.6) for 10 minutes, and with copper sulphate 0.5% for 5 minutes. Cells were counterstained with hematoxylin.
For detection of surface antigens, cells were fixed with 1% paraformaldehyde diluted in PBS for 5 minutes followed by rinsing with PBS containing 0.1% bovine serum albumin (BSA) and 0.02% sodium azide. Immunofluorescence staining was performed with MoAbs CD2, CD3, CD4, CD7, CD8 (as T-cell markers), CD10, CD19, CD20, CD21, CD22, CD34, TdT, HLA-DR, K, A, and CD73.
After rinsing twice, FITC-conjugated rabbit antimouse IgG with 2% pooled human serum and 10% rabbit serum was added for 30 minutes. Cells were rinsed twice and resuspended in 0. We intentionally did not use the term null-ALL for this last type of ALL because the meaning of null-ALL has changed with the acquisition of more MoAbs.
Radiochemical assay. 5'NT was determined radiochemically as follows. Cells were suspended in 50 mmol/L Tris buffer, pH 7.4, and 1 mmol/L EDTA at a density of 5 x lo6 cells/mL. Cells were disrupted by sonification on ice with four bursts of 5 seconds with 10-second intervals. Twenty microliters of this lysate was added to a mixture of 6 p L 25 mmol/L MgCl,, 4 FL distilled water, and 5 pL 1.64 mmol/L IMP (three parts 1.9 mmol/L IMP and one part 8-"C-IMP). Thus, cells were exposed to a final concentration of 0.235 mmoVL IMP as a substrate. In simultaneously performed duplicate experiments, 4 pL 20 mmol/L +methylene adenosine diphosphate (AOPCP) was added as an inhibitor of 5"T instead of distilled water. The incubations were performed at 37°C for 30 minutes and terminated by heating at 95°C for 5 minutes. After centrifugation, 5 IJ.L of the mixtures was spotted onto PEI-thin layer chromatography sheets. IMP, inosine, and hypoxanthine were separated on distilled water; the spots were identified under UV light (254 nm), cut out, and quantitated by liquid scintillation counting. Enzyme activities were expressed as nanomoles of IMP converted to inosine and hypoxanthine per hour per lo6 cells. 5'NT was defined as the AOPCP-inhibited fraction. The results shown are the means of duplicate determinations. The median coefficient of variation of the individual determinations is 4.7%.
Statistical testing was performed with the Xz-test and the Mann-Whitney U test at a two-sided significance level of 0.05.
Definitions.
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RESULTS
There were 19 T-ALL samples and 83 samples of B-cell lineage including the two cell lines. Four samples were A good linear correlation was found between the percentage of 5"T' cells determined by the FACS and the 5 " T activity determined by the radiochemical assay (r = 36; r = 3 4 if only B cells were evaluated; Fig 1) . The percentage of 5'NT' cells is related to the immunologic subtypes, as shown in Table 1 and Fig 2. The radiochemical 5'NT activity of the different immunologic subtypes is shown in Table 1 and Fig 3. It is clear that in the least mature stage I the 5"T expression is low. It is high in the CD10' stages I1 and I11 and low again in stage IV. 5'NT was low in T-ALL, including one CD10' T-ALL.
We evaluated whether there was a correlation between the expression of 5'NT and other differentiation antigens of the B-cell lineage. No significant correlation could be detected between the percent of cells positive for 5'NT and the percent of cells positive for CD20, CD21, CD22, CD34, or TdT. For CD19 and HLA-DR, such a correlation was not performed because all B-lineage samples were positive for these two antigens.
There was a significant correlation between the percent of CD10' and 5'NT+ cells (P < .05; Table 2 ). The mean (+SD) 5'NT activity of CD10-samples was 6.1 + 12.2 Table 1 Table 1 and Figs 2 and 3; several CD10' cases were even 5'NT-. High 5'NT activities were not found in stages I and IV, but were always associated with CDlO expression. Two-color fluorescence studies have been performed in a few cases (Fig 4) . These confirm the relationship between S'NT and CDlO expression. Cases that were CD10' ck-and cases that were CD10' cp+ did not show significant differences in S'NT expression. Among stage I11 samples, the number of CD10-cp+ samples was too low (n = 3) to compare their S'NT activity with that of CD10' ck+ cases.
Within the CD10+ group, there was no significant correlation between the percent of cells positive for 5'NT and the percent of cells positive for cp, CD20, CD21, CD22, CD34, and TdT.
A significant inverse correlation between the percent of cells positive for K or A and the percent of cells positive for 5'NT was found (P < -01; Table 2 (median 0.6) of K/A+ samples. The three CLL samples were K+ or A+ and were therefore classified as stage IV B-cell leukemias. The percentages of 5'NT' cells of these samples were 31.5%, 0.8%, and 1.4%. In the latter two cases, S'NT activity was determined radiochemically: 0.9 and 0.1 nmol/ h/106 cells. These data are also shown in Figs 2 and 3.
Cell line 1254 is a spontaneous mutant of WI-L2. 1254 shows a more mature phenotype with K expression and is S'NT-, opposite to WI-L2 cells, which are K-and S'NT+.
DISCUSSION
Up to now the relationship of 5 " T to B-cell maturation, in particular in the very early stages of B-cell development, has not been clearly defined. In this study we established the place of 5'NT in the maturation scheme by comparing its expression, determined by immunocytochemical and radiochemical assays, in relation to a panel of other differentiation antigens. Leukemic B-cell-lineage samples were categorized into four stages depending on their expression of sIg, cp, and CDIO. Stage I (pro-B) samples did not express any of these three markers. The B-cell origin of these samples was confirmed by the expression of CD19 and HLA-DR. According to the model of Nadler et a1,I6 pro-B cells are of a less mature type than the cells that already express CD10*6~'7 and that were called stage I1 in the After staining with antisera against these antigens that are, respectively, of the lgG2a and of the lgGl subclass, the second step was performed using a phycoerythrin (PE)-conjugated rabbit antiserum specifically directed against the mouse lgG2a in case of CD73 and an FITC-conjugated rabbit antiserum specifically directed against the mouse lgGl in case of CD10.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Our results clearly show that the median 5'NT is low or absent in the stage I pro-B cells, increases to very high activities in the CD10' stages I1 and 111, and decreases again in stage IV. 5'NT is only expressed on the cell surface together with CD10, but is clearly not present on all CD10' leukemias. This finding is reflected in the wide ranges of 5'NT activities in stages I1 and 111. In conclusion, 5'NT is expressed in CD10' stages and its activity decreases before K or h appears on the cell surface.
Our findings are based on a study of malignant cells and it can be questioned whether the results can be extrapolated to normal B cells. A study to determine the 5 " T activity of non-malignant CDlO' cells has to show whether the high 5'NT activity on leukemic CD10' cells is a malignant phenomenon or a normal maturation phenomenon. In a previous report we have used a histochemical lead staining method that is less sensitive than the methods used in the present report to study the prognostic significance of 5'NT in a group of 33 children with CD10' ALL. It appeared that a high 5'NT activity was related to a poorer prognosis among children with CD10+ ALL. This prognostic factor was found to be independent from sex, age, and white blood cell count." Very recently, other investigators confirmed the prognostic significance of 5'NT activity among adults with CD10' &LeL9
Several hypotheses have been postulated to explain the prognosticvalue of 5'NT by its possible role in resistance to the thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) or to methotrexate.20r21 If 5 " T plays an important role in drug resistance, one could expect an increased sensitivity of T-cell leukemias to methotrexate or thiopurines. The sensitivity to these drugs depends, however, on many other factors that might differ between T-ALL and B-lineage ALL. For example, the activity of hypoxanthine-guanine phosphoribosyl transferase (HG-PRT), the enzyme that converts the inactive 6-MP and 6-TG to their cytotoxic nucleotides, is lower in T-ALL than in B-lineage ALL. 22 Recent findings suggest that 5'NT plays a role in signal transduction pathways and lymphocyte proliferation. CD73 antibodies stimulated DNA synthesis specifically in 5'NT' lymphocytes. Also, CD73 antibodies induced a fraction of normal B cells to leave Go phase and enter the G, phase of the cell cycle. The same antibodies stimulated 3H-thymidine uptake in malignant B cells from patients with CLL.Z3,'' Thus, 5'NT' CD10' ALL cells might have different control mechanisms of cell proliferation than 5'NT-CD10' ALL cells. The present study did not show differences in expression of other B-cell antigens between 5'NT' CD10' and 5'NT-CD10' ALL.
We conclude that the place of 5'NT (CD73) in leukemias corresponding to stages of early B-cell development has been characterized. Future studies should make clear whether a high expression of this enzyme in CD10' leukemias is a normal maturation phenomenon or a malignant phenomenon. The role of 5'NT in drug resistance and cell proliferation has to be studied.
